ASTER-GUARDIANS
15.5.2023 15:28:35 CEST | Business Wire | Press release
Margaret Helen Shepherd from UK has been announced as the winner of the Aster Guardians Global Nursing Award 2023 in a prestigious award ceremony held at Queen Elizabeth II Centre in London. The winner was announced by Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare and the award was presented by Professor Jamie Waterall, Deputy Chief Public Health Nurse for the Office of Health Improvement & Disparities at Govt. of UK alongside Ms. Sheila Sobrany – President of Royal College of Nursing; Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare; and Mr. TJ Wilson – Executive Director and Group Head – Governance & Corporate Affairs, Aster DM Healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005491/en/
Margaret Helen Shepherd from the UK - Winner of the Aster Guardians Global Nursing Award 2023 (Photo: AETOSWire)
Launched on International Nurses Day in May 2021 by Aster DM Healthcare, with an aim to recognise the selfless contribution of nurses to millions of patients worldwide, Aster Guardians Global Nursing Award 2023 received an overwhelming response from nurses worldwide with over 52,000 nurses from 202 countries, a 116% growth from the last edition which had received 24,000 applications.
The award ceremony also saw a special video message from Dr. Tedros Adhanom Ghebreyesus – Director General of World Health Organisation being played to congratulate all the finalists and thank Aster DM Healthcare for the initiative.
On winning the award, Nurse Margaret said, “I am deeply humbled and grateful to receive the prestigious Aster Guardians Global Nursing Award. As healthcare professionals, we are privileged to be able to make a positive impact on the lives of our patients, and I feel blessed to be part of such a rewarding profession. This award not only recognises my personal achievements but also highlights the importance of nursing as a critical component of healthcare. Thank you to all my colleagues, mentors, and patients who have supported me throughout my career.”
Margaret has been dedicated to improving diabetes care through better diagnosis. She is the leading nurse for monogenic diabetes in the UK and provides advice to clinicians across the world regarding the management of this condition. She set up a national network of genetic diabetes nurses in 2002 to increase awareness of this condition (which is initially misdiagnosed in 80% of cases, resulting in patients being treated with unnecessary insulin injections). She was one of 70 national NIHR70@70 Senior Nurse Research Leaders (driving innovation and new roles to increase research awareness and engagement within clinical care) and has received the prestigious Florence Nightingale Foundation Leadership Scholarship.
Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said, “We are honoured to announce Ms Margaret Helen Shepherd from the United Kingdom as the winner of this year's Aster Guardians Global Nursing Award. She has exemplified the highest standards of patient care and dedication that is inspirational, and it deserves global recognition. Each one of the top 10 finalists have done phenomenal work and the Grand Jury had a tough time assessing and selecting the final winner. We are privileged to offer Aster Guardians Global Nursing Award as a platform to share and honor the accomplishments of exceptional nurses from around the globe.”
Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare said, “Aster Guardians Global Nursing Award is a small yet significant expression of gratitude that aligns with this year's International Nurses Day theme, ‘Our Nurses. Our Future’. Nurses ensure that patients receive high-quality care and often go beyond their call of duty to ensure that the right care is provided. This often helps them develop into other areas like research, innovation, mentorship, education, digitization among others as the stories of this year’s finalists and the winner have showcased. We as individuals and organizations must ensure that they receive the recognition they deserve, and this is where initiatives like Aster Guardians Global Nursing Award come into play. As a group, we will continue to support and celebrate the tireless efforts of nurses and put forth their inspiring stories of excellence.”
The rest of the 9 finalists, Cathy Cribben-Pearse from UAE, Christine Mawia Sammy from Kenya, Gloria Ceballo from Panama, Jincy Jerry from Ireland, Lilian Yew Siew Mee from Singapore, Michael Joseph Dino from Philippines, Shanti Teresa Lakra from India, Teresa Fraga from Portugal, and Wilson Fungameza Gwessa from Tanzania were also awarded with a monetary prize.
These nurses were selected through a stringent review process run by Ernst & Young LLP, a panel of Screening-Jury and the Grand Jury.
About Aster DM Healthcare
Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 30 hospitals, 125 clinics, 496* pharmacies, 20 labs and 157 patient experience centers in seven countries, including India. We reach out to all economic segments in the GCC states through our differentiated healthcare services across the “Aster”, “Medcare” and “Access” brands.
* Including 239 Pharmacies in India operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005491/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom